Journal of Viral Hepatitis

• Medicaid Restriction Removal Increased HCV Treatment Rates Access to treatment improved after Medicaid-imposed restrictions were removed, but more policy changes are needed to address remaining disparities.
  Journal of Viral Hepatitis, May 16, 2022
• HCV-Related Depression, Anxiety, and Cognitive Improvements Chronic HCV patients may realize neuropsychiatric and cognitive improvements after achieving sustained virological response with direct-acting antiviral agents.
  Journal of Viral Hepatitis, May 09, 2022
• HCV Cascade of Care Among People Living With HIV This study characterized the HCV care cascade among people living with HIV in New South Wales, comparing HCV testing and treatment uptake between pre- and post-introduction of DAAs in Australia.
  Journal of Viral Hepatitis, April 25, 2022
• Integrating HCV Screening of Baby Boomers at a Hospital ED This paper details the implementation of an opt-in HCV screening program for baby boomers presenting to a community hospital emergency department.
  Journal of Viral Hepatitis, April 18, 2022
• Tenofovir vs. Entecavir Therapy in HBV: Long-term Renal Safety Do tenofovir and entecavir differ in their long-term impact on renal function in patients with hepatitis B?
  Journal of Viral Hepatitis, April 11, 2022
• Chronic Hepatitis D--What Is Changing? Several new approaches to hepatitis D virus therapy have been explored in recent years. Review these advances and novel therapeutic options for HDV in this paper.
  Journal of Viral Hepatitis, April 04, 2022
• Hepatitis D Hospitalizations in the U.S.: 2010-2018 A new study provides insight into the hospitalization rates of hepatitis D in the U.S. and the various characteristics of these patients.
  Journal of Viral Hepatitis, March 31, 2022
• The Impact of Waves of COVID-19 on HBV and HCV Testing In what ways were HBV and HCV testing impacted during the first three waves of the COVID-19 pandemic? A new study examines the trends.
  Journal of Viral Hepatitis, March 17, 2022
• E-Nose vs Quadrupole Mass Spectrometry for Identifying HCV This study suggests that E-Nose technology can be an economical, easy-to-use, portable and non-invasive tool for screening and early diagnosis of HCV infection.
  Journal of Viral Hepatitis, March 07, 2022
• Role of Gut Microbiota in HBV Disease Progression and Treatment This review aims to clarify our understanding of the pathophysiology of gut microbiota and their relationship with liver injury in chronic hepatitis B. How might this inform future therapeutics?
  Journal of Viral Hepatitis, February 21, 2022
• Long-term Changes of Liver Stiffness in DAA Anti-HCV Therapy How does SVR impact the degree of fibrosis in the long-term after direct-acting antiviral HCV therapy? This study compared early vs. the long-term changes in liver stiffness that occur after therapy.
  Journal of Viral Hepatitis, January 31, 2022
• DAAs and Risk of Tumour Progression of HCC After Treatment Does DAA-induced SVR significantly reduce the risk for tumor progression and liver-related death following curative treatment?
  Journal of Viral Hepatitis, January 24, 2022
• Efficacy of an eConsult Service to Cure HCV in Primary Care This paper evaluated an eConsult system that provides individualized treatment recommendations from specially trained pharmacists and primary care physicians to other PCPs regarding HCV care.
  Journal of Viral Hepatitis, January 17, 2022
• COVID-19 and the Liver: Lessons Learnt a Year Later This study summarizes what we have learned concerning liver manifestations and prevalence of hepatic abnormalities in COVID-19 patients from both Eastern and Western countries.
  Journal of Viral Hepatitis, January 10, 2022
• Viral and Bacterial Factors of Mother-to-Child HBV Transmission Mother-to-child transmission of HBV during delivery remains a common route of infection in developing countries. What role do viral and bacterial factors play in such cases?
  Journal of Viral Hepatitis, January 03, 2022
• Neuropsychological Effects of DAA Treatment for HCV Subjects Does HCV treatment with direct-acting antiviral agents have an impact--either positive or negative--on neurocognitive functioning?
  Journal of Viral Hepatitis, December 20, 2021
• DAAs for HCV-related HCC Patients With Multiple Recurrences Does treatment with direct-acting antivirals have a beneficial effect on HCV-related hepatocellular carcinoma patients who have had multiple courses of recurrence?
  Journal of Viral Hepatitis, December 13, 2021
• Financial Incentives for HCV Testing and Treatment Uptake Financial incentives can encourage HCV testing and treatment, but how would such incentives impact the overall cost of finding and diagnosing people with HCV infection?
  Journal of Viral Hepatitis, December 06, 2021
• The Patient Perspective on Future Hepatitis B Treatment Through qualitative interviews, this survey of patients living with chronic HBV explored their preferences and opinions regarding future treatments.
  Journal of Viral Hepatitis, November 29, 2021
• HCV Care Cascade in Persons Experiencing Homelessness This review highlights the effectiveness of community-based programs in achieving relatively high rates of linkage to HCV care among the homeless.
  Journal of Viral Hepatitis, November 22, 2021